Yokohama, Japan:August 18 2025 - REPROCELL is proud to announce the introduction of NeoSight - Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications.
[...]
This is an abstract of the document. To keep reading, click here and get access to the original version.